ABSTRACT ␥-Hydroxybutyrate (GHB) is a psychotropic compound endogenous to the brain. Despite its potentially great physiological significance, its exact molecular mechanism of action is unknown. GHB is a weak agonist at GABA B receptors, but there is also evidence of specific GHB receptor sites, the molecular cloning of which remains a challenge. Ligands with high affinity and specificity for the reported GHB binding site are needed for pharmacological dissection of the GHB and GABA B effects and for mapping the structural requirements of the GHB receptorligand interactions. For this purpose, we have synthesized and assayed three conformationally restricted GHB analogs for binding against the GHB-specific ligand [
␥-Hydroxybutyrate (GHB) is a naturally occurring substance in the mammalian brain, where it is currently believed to function as a neurotransmitter or neuromodulator (Bernasconi et al., 1999) . GHB is a registered drug for the treatment of cataplexy associated with narcolepsy (Fuller and Hornfeldt, 2003) and has also displayed therapeutic potential for treating drug and alcohol dependence (Gallimberti et al., 2000) . Furthermore, GHB is a drug of abuse (Wong et al., 2004) , producing mild euphoria, muscle relaxation, sedation, and eventually coma with increasing dosage. Despite the obvious biological and pharmacological importance of GHB, its exact mechanism of action remains elusive.
Most of the reported GHB effects are mediated through the GABA system, in particular GABA B receptors. GHB has been shown to be a low-affinity (Mathivet et al., 1997) weak partial agonist at GABA B receptors (Lingenhoehl et al., 1999) and may also be converted into GABA in vivo and thus affect GABA receptors indirectly (Hechler et al., 1997) . However, based on recent data, it would also seem that specific GHB receptor-mediated effects exist (Castelli et al., 2003; Kemmel et al., 2003; Brancucci et al., 2004) . This, in combination with the presence of high-affinity [ 3 H]GHB binding sites in the brain (Benavides et al., 1982) , suggests the existence of a distinct GHB receptor. In further support of this view, brains from GABA B(1) receptor knock-out mice still exhibit [ 3 H]GHB binding (Kaupmann et al., 2003; Wu et al., 2004) , demon-strating that GHB and GABA binding sites are separate entities. NCS-382, a synthetic structural analog of GHB and a purported antagonist of the GHB receptor (Castelli et al., 2004) , has been shown to compete with [ 3 H]GHB for the high-affinity sites. Radioligand binding studies have demonstrated [ 3 H]NCS-382 to be selective for GHB binding sites, making it a valuable tool for probing the putative GHB receptor (Mehta et al., 2001) . One recent report claimed the cloning of a GHB-specific receptor yet failed to show affinity of NCS-382 for the receptor . Furthermore, the in situ hybridization expression pattern of this claimed receptor in rat brain showed labeling in the cerebellum, whereas previous autoradiography studies performed with [ 3 H]GHB and [ 3 H]NCS-382 showed negligible binding in this region of the brain (Snead, 1996; Gould et al., 2003) . The dual action of GHB is a major obstacle when studying GHB receptor-mediated effects and accentuates the need for potent and selective ligands. Also, higher affinity compounds could aid the molecular cloning of GHB receptors, which remains the most prominent goal of this line of research.
So far, the structural requirements of GHB binding sites are relatively unexplored (Bourguignon et al., 2000; Macias et al., 2004) . Most attempts have been to generate GHBselective compounds that do not undergo metabolism to GABA-ergic compounds. Albeit the high value for in vivo studies, these compounds have at best been equipotent with GHB (Wu et al., 2003; Carter et al., 2005) . In addition, the conformational flexibility of previous ligands and limited stereospecificity data associated with them would hamper any attempt to map the GHB receptor pharmacophore. Therefore, we set out to synthesize a series of conformationally restricted GHB analogs, with close attention to stereochemistry. Herein, we report the synthesis and pharmacological evaluation of the enantiomers of three highly selective GHB ligands. To our knowledge, one of these compounds, (R)-3-hydroxycyclopent-1-enecarboxylic acid [(R)-HOCPCA)], is one of the most high-affinity GHB receptor ligand reported to date (structure is shown in Fig. 1 ). 
Materials and Methods

Compounds and Radioligands
Synthesis
The racemic compounds (RS)-3-hydroxycyclopent-1-enecarboxylic acid [(RS)-HOCPCA] and (RS)-3-hydroxycyclohex-1-enecarboxylic acid [(RS)-HOCHCA] were synthesized in several steps (Supplemental Data, Scheme 1). Ethyl 2-oxocyclopentanecarboxylate and ethyl 2-oxocyclohexanecarboxylate were converted into the respective unsaturated esters (Beagley et al., 1989; Palaty and Abbott, 1995) . Allylic oxidation of the unsaturated ethyl esters with CrO 3 by a procedure similar to that described previously for the methyl esters (Lange and Otulakowski, 1982; Lange et al., 1989) gave the respective enone esters (Mori, 1978) . These were converted by selective reductions (Gemal and Luche, 1981; Cossy et al., 1995) with the aid of NaBH 4 -CeCl 3 to the respective allylic alcohols. Treatment with aqueous Na 2 CO 3 gave the unsaturated hydroxy acids. Finally, these were resolved by chiral high-performance liquid chromatography using a ChiralPak AS-H column (Daicel Chemical Industries, Tokyo, Japan) into the pure enantiomers (S)-HOCPCA (98.1% ee) and (R)-HOCPCA (97.6% ee) as well as (S)-HOCHCA (97.6% ee) and (R)-HOCHCA (96.4% ee), respectively. The absolute configurations of (Pajouhesh et al., 2000) , followed by ester hydrolysis.
Assigned structures were in agreement with the 1 H (300 MHz) and 13 C (75 MHz) NMR spectra. Elemental analyses were performed at the Analytical Research Department (H. Lundbeck A/S, Copenhagen, Denmark) or by J. Theiner (Microanalytical Laboratory, Department of Physical Chemistry, University of Vienna, Austria). Further details concerning synthesis and purification are given in Supplemental Data.
Binding Assays
Membrane Preparations. All binding assays were performed using rat brain synaptic membranes of the cortex and central hemispheres from adult male Sprague-Dawley rats with tissue preparation as described earlier by Ransom and Stec (1988) . On the day of the assay, the membrane preparation was quickly thawed, suspended in 40 volumes of ice-cold 50 mM Tris-HCl buffer (pH 7. Mehta et al. (2001) was adapted to a 96-well format filtration assay (Kaupmann et al., 2003 jpet.aspetjournals.org g of protein/aliquot) in KH 2 PO 4 buffer (50 mM, pH 6.0) were incubated with [ 3 H]NCS-382 in triplicate at 0°C for 1 h in a total volume of 200 l. Nonspecific binding was determined using unlabeled GHB (1 mM). The binding reaction was terminated by rapid filtration through GF/C unifilters (PerkinElmer Life and Analytical Sciences) using a 96-well Packard FilterMate cell harvester followed by washing with 3 ϫ 250 l of ice-cold binding buffer. Microscint scintillation fluid (PerkinElmer Life and Analytical Sciences) was added to the dried filters, and the amount of filter-bound radioactivity was quantified in a Packard TopCount microplate scintillation counter (PerkinElmer Life and Analytical Sciences). (Hill and Bowery, 1981) . Nonspecific binding was determined using 0.1 mM baclofen. Binding was terminated by filtration through Whatman GF/C filters (Whatman Schleicher and Schuell, Keene, NH) using a Brandell M-48R cell harvester, filters were washed with 3 ϫ 3 ml of ice-cold buffer, and filter-bound radioactivity was counted in a Packard Tricarb 2100 liquid scintillation analyzer using 3 ml of Opti-fluor scintillation fluid (PerkinElmer Life and Analytical Sciences). The Bradford (1976) protein assay was used for protein determination using bovine serum albumin as a standard, according to the protocol of the supplier (Bio-Rad, Hercules, CA).
Data Analysis. The binding data were analyzed by nonlinear regression curve-fitting using Prism 4.0b (GraphPad Software Inc., San Diego, CA). Where indicated, K i values were calculated from IC 50 values by means of the Cheng-Prusoff equation (Cheng and Prusoff, 1973) . (Kaupmann et al., 2003) . All generated inhibition curves were therefore fitted using a one-site model. GHB and known structural analogs (Fig. 1) were found to inhibit [ 3 H]NCS-382 binding (16 nM) in a concentrationdependent manner, and the rank order of affinity was NCS-382 Ͼ T-HCA Ͼ GHB ( Fig. 2A; Table 1 ), which is in agreement with the literature (Bourguignon et al., 2000; Mehta et al., 2001 ). The specific amount of bound [
Results
Inhibition
3 H]NCS-382 inhibited by 1 mM GHB was at least 90% of total binding.
Having established our assay to be reliable and reproducible, the affinities of the three novel GHB analogs synthesized in our laboratory were measured (depicted in Fig. 1 ). HOCHCA and HOCPCA were initially tested as racemic mixtures, whereas both the (R,R) and (S,S) forms were tested for HOCPrCA, which was synthesized from asymmetric precursors. Table 1 shows that the racemic mixtures of HOCHCA and HOCPCA inhibit [
Fig. 2. Concentration-dependent inhibition of [ 3 H]NCS-382 binding to rat synaptic membranes by the established compounds GHB, T-HCA, and NCS-382 (A) and by the novel cyclic analogs (S,S)-and (R,R)-HOCPrCA (B), (S)-and (R)-HOCHCA (C), and (S)-and (R)-HOCPCA (D)
3 H]NCS-382 binding with K i values of 0.48 and 0.16 M, respectively, indicating that these cyclic GHB analogs have correspondingly 9 and 27 times higher affinity than GHB itself. It is interesting that, for the cyclopropyl analog HOCPrCA, the (R,R) form (K i of 1.1 M) was approximately 10-fold better than the (S,S) form ( Fig. 2B ; Table 1 ). This prompted us to resolve the racemic mixtures of HOCHCA and HOCPCA into (R) and (S) forms and measure their affinities. As illustrated in Fig. 2 , C and D, respectively, (R)-HOCHCA (K i of 0.48 M) has 70-fold higher affinity than (S)-HOCHCA for GHB binding sites. Likewise, (R)-HOCPCA (K i of 0.11 M) has 13-fold higher affinity than (S)-HOCPCA. We also analyzed the importance of the hydroxyl group at the 3-position of HOCPCA by testing the corresponding ketone, 3-oxocyclopent-1-enecarboxylic acid (OxCPCA) (Fig. 1) . The presence of an oxo group instead of a hydroxyl group greatly attenuated the ability to compete for [ 3 H]NCS-382 binding (Table 1) . This demonstrates that the GHB binding site interacts stereospecifically with its substrates and that the hydroxyl group of HOCPCA is essential for the high affinity of this compound.
Selectivity Studies. The selectivity of HOCHCA and HOCPCA for GHB binding sites over GABA B and GABA A receptors was investigated in binding assays using tritiated GABA and muscimol for respective labeling of the receptors. In each case, GABA inhibited binding as expected. Figure 3 and Table 2 show that GHB binds to GABA B receptors with low affinity (IC 50 of 230 M) as reported by others (Mathivet et al., 1997) . However, IC 50 values of the racemic mixtures of HOCHCA and HOCPCA are not reached at concentrations of 1 mM (changes in specific binding of Ϫ17 Ϯ 3 and Ϫ14 Ϯ 1%, respectively) ( Fig. 3; Table 2 ), nor do the two compounds possess any affinity for the GABA site of the GABA A receptor at 1 mM concentrations, as measured by [ 3 H]muscimol binding (no significant decrease in specific binding) ( Table 2 ). These results demonstrate that HOCHCA and HOCPCA are selective for GHB binding sites/GHB receptors over GABA receptors.
Discussion
Although the pharmacological effects of GHB have been the subject of many investigations in recent years, the role of specific GHB receptors remains unclear. It has been demonstrated in numerous studies that GHB causes stimulation of GABA B receptors, thus complicating and possibly masking the measurement of native GHB receptor-mediated effects (Carai et al., 2001; Jensen and Mody, 2001; Nava et al., 2001; Barbaccia et al., 2002; Kaupmann et al., 2003; Ren and Mody, 2003) . As a consequence, the biological significance and mere existence of a GHB receptor have been questioned. The fact that the unique overlapping [
3 H]GHB and [ 3 H]NCS-382 high-affinity binding sites exist in mammalian brain (Mehta et al., 2001; Gould et al., 2003) and that these remain intact in mice lacking functional GABA B receptors (Kaupmann et al., 2003; Wu et al., 2004) , however, stand in favor of a distinct GHB binding site or receptor. This has already been suggested based on the differential expression profile and ontogeny of GABA B and specific GHB binding sites (Snead, 1996) . Therefore, in the GHB field, there is a clear need for the development of potent and selective compounds.
In this work, we have explored the affinity and stereoselectivity of three cyclic ligands for the putative GHB receptor with a view to obtaining new lead structures and pinning down the precise geometry required for activity. For the first time, we have separately examined the trans-enantiomers of HOCPrCA (Bourguignon et al., 2000) . The cyclopentene and cyclohexene compounds are entirely novel as GHB ligands Table 2 . (Bourguignon et al., 2000; Mehta et al., 2001) . Compared with GHB, T-HCA contains a double bond between the ␣-and ␤-carbons, eliminating folded conformations and increasing the affinity by a factor 4. NCS-382 is somewhat more constrained by a semirigid seven-membered ring system and has approximately 15 times higher affinity than GHB, part of which may be attributed to the incorporation of a benzene ring. Nonetheless, NCS-382 still leaves a number of possibilities open for the optimal geometric relationship between the main pharmacophore elements, the hydroxyl and carboxylate moieties. In keeping with this theme of conformational restriction, the newly characterized analog offering the greatest spatial repertoire for these groups, HOCPrCA, is also the weakest inhibitor, but the introduction of two stereocenters and observation of 10-fold stereoselectivity further narrows down the pharmacophore. In the two novel GHB structures, the ␣ and ␥ carbons of GHB are locked in a ring for the first time, and the R-isomer of the cyclopentene derivative HOCPCA has as much as 39 times higher affinity than GHB, indicating that this structure closely mimics the bioactive conformation of the endogenous ligand. Similar to HOCPrCA and in accordance with the observations made by Castelli et al. (2002) for NCS-382, the new analogs bind to the GHB receptor in a stereoselective manner. Thus, the alignment of GHB at its specific recognition sites is essentially solved and the structural preferences of the receptor in this vicinity are largely mapped out, with the corollary that GHB most likely takes on a different conformation when binding to GABA B receptors.
The only major feature not pinpointed by these analogs is the hydroxyl proton. Because conversion of the hydroxyl group of HOCPCA to a carbonyl group greatly abolishes the affinity of this scaffold, it is tempting to conclude that the hydroxyl group donates an important hydrogen bond to the GHB receptor. However, it was recently shown that the less polar 3-chloropropanoic acid inhibits [ 3 H]NCS-382 binding with only slightly less efficiency than GHB, challenging the concept that hydrogen bond donation is essential for binding (Macias et al., 2004) . Conversely, the oxo group in OxCPCA forces the distal hydrogen bond acceptor into the plane of the ring and the carboxylate group, a distinctly different arrangement from that of the active analogs, leaving the precise role of the hydroxyl proton yet to be determined.
With the demonstration that, unlike GHB, the two best binding inhibitors HOCPCA and HOCHCA are devoid of affinity for the GABA receptors, these compounds represent exciting new tools for studying GHB pharmacology both in vivo and in vitro. An obvious advantage of HOCPCA and HOCHCA is their low molecular weights, which make them potential blood-brain barrier penetrants, although this has not been tested as of yet. In this context, it will be necessary to determine the intrinsic activity of the compounds. Although isolated reports of functional assays have been described in the literature (Castelli et al., 2003; Kemmel et al., 2003; Brancucci et al., 2004) , these remain to be validated by other laboratories. The compounds are also ideal lead structures, presenting ample opportunity for further substitution and structural elaboration, again with the advantage of low molecular weight and high binding efficiency of the scaffolds, bearing in mind that the synthesis of a radioligand with high specific activity could greatly aid in the molecular cloning of the GHB receptor or lay the way for tomography studies. In addition, combining the stereospecificity data obtained here with the structure-activity relationships from this and previous studies paves the way for a more complete pharmacophore model of the extended GHB binding site. Therefore, this work offers a platform for further efforts in both pharmacology and medicinal chemistry toward the final goal of characterizing and understanding the physiological role of the GHB receptor.
